InnoCare Pharma discovers and develops novel therapies for the treatment of cancer and autoimmune diseases.
Business Model:
Revenue: $209k
Employees: 201-500
Address: No. 8 Life Science Park Road
City: Beijing
State: beijing municipality
Zip: 100084
Country: CN
InnoCare Pharma discovers and develops novel therapies for the treatment of cancer and autoimmune diseases.
Contact Phone:
Contact Email:
Listed Exchange:
Hong Kong Stock Exchange
IPO Date:
3/20/2020
IPO Valuation:
$1B
Ticker Symbol:
9969
IPO Price:
$1.1538910301410519/share
Amount Raised:
$289M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2020 | IPO | $288M |
|
1/2019 | Private Equity Round | $0 |
Vivo Capital Jianxin Capital Loyal Valley Capital Loyal Valley Capital Vivo Capital Jianxin Capital Loyal Valley Capital Loyal Valley Capital |
2/2021 | Post-IPO Equity | 2 | - |
Hillhouse Capital Group Vivo Capital Hillhouse Capital Group Vivo Capital Hillhouse Capital Group Vivo Capital Hillhouse Capital Group Vivo Capital |
2/2018 | Private Equity Round | 2 | $55M |
Vivo Capital CCB International Vivo Capital Vivo Capital CCB International Vivo Capital |
1/2019 | Equity | 3 | $160M |
Loyal Valley Capital Vivo Capital Jianxin Capital Loyal Valley Capital Loyal Valley Capital |
2/2021 | Post-IPO Equity | 2 | - |
Hillhouse Capital Group Vivo Capital Hillhouse Capital Group Vivo Capital Hillhouse Capital Group Vivo Capital Hillhouse Capital Group Vivo Capital |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|